Enter inventor name

Michael Nicholas Greco

This inventor holds 46 USPTO granted patents and 9 published patent applications, plus 1 CIPO patent and 10 EPO patents, primarily in Pharmaceutical Formulations. Top assignees: Janssen Pharmaceutica Nv, Ortho-Mcneil Pharmaceutical Corp., Beta Pharma, Inc.. Active years: 1991-2026.

USPTO Granted Patents = 46 (Patent Applications = 9)

% Patents Active = 50.0

CIPO Patents = 1 (Patent Applications = 7)

EPO Patents = 10 (Patent Applications = 18)

Average Co-Inventor Count = 4.5

ph-index = 5

Forward Citations = 67(Granted Patents)

Location History:

Spring House, PA (US) (2013)
Lansdale, PA (US) (1991 - 2022)

Company Filing History:

19 out of 2,099

Janssen Pharmaceutica Nv

patents

14 out of 363

Ortho-Mcneil Pharmaceutical Corp.

Beta Pharma (Shanghai) Co., Ltd.

patent

5. 1 out of 377

Ortho Pharmaceutical Corporation

patents

where one patent can have more than one assignee

Years Active: 1991-2026

Loading Chart...

Areas of Expertise:

Pharmaceutical Formulations

EGFR Inhibitors

CDK Inhibitors

Therapeutic Uses

Indazole Derivatives

Serine Protease Inhibitors

Anilinopyrimidine Derivatives

Cancers Treatment

Quinoline Derivatives

Benzimidazole Derivatives

Asthma Treatment

Vasopressin Receptor Antagonists

46 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12595246 - Crystalline and amorphous forms of N-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof (2026-04-07),

2. 12390464 - Treatment of EGFR mutant-related cancers using a combination of EGFR and CDK4/6 inhibitors (2025-08-19),

3. 12258365 - Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof (2025-03-25),

4. 12187707 - Pharmaceutical formulations of-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylaminde and salts thereof (2025-01-07),

5. 11414401 - Substituted 2-anilinopyrimidine derivatives as EGFR modulators (2022-08-16),

6. 11352341 - 2H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereof (2022-06-07),

7. 11180478 - Pharmaceutical formulations of N-(2-(2-(dimethylamino) ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof (2021-11-23),

8. 11052086 - 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers (2021-07-06),

9. 10844045 - Pharmaceutical salts N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof (2020-11-24),

10. 10590111 - Substituted 2-anilinopyrimidine derivatives as EGFR modulators (2020-03-17),

11. 10239864 - 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof (2019-03-26),

12. 10118900 - Benzimidazole derivatives useful as CB-1 inverse agonists (2018-11-06),

13. 9878994 - 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof (2018-01-30),

14. 9815790 - Chemically modified quinoline and quinolone derivatives useful as CB-1 inverse agonists (2017-11-14),

15. 9732061 - Cinnoline derivatives useful as CB-1 receptor inverse agonists (2017-08-15),

Title: Michael Nicholas Greco: Innovator in Pharmaceutical Formulations

Introduction: Michael Nicholas Greco, based in Lansdale, PA, has made significant contributions to the field of pharmaceuticals, with a remarkable portfolio consisting of 43 patents. His innovations primarily focus on the development of targeted therapies aimed at treating various medical conditions, including cancers related to epidermal growth factor receptor (EGFR) mutations.

Latest Patents: Greco's latest patents include groundbreaking formulations that target specific diseases through innovative molecular designs. One notable patent details "Pharmaceutical formulations of (2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and its salts." This formulation aims to treat or prevent diseases mediated by mutated forms of the EGFR, particularly various cancers. Another significant patent describes "Substituted 2-anilinopyrimidine derivatives as EGFR modulators." This application presents novel derivatives useful for treating cancer through EGFR modulation, highlighting Greco's commitment to advancing cancer therapies.

Career Highlights: Throughout his career, Michael Nicholas Greco has collaborated with prominent companies in the pharmaceutical sector, including Janssen Pharmaceutica and Ortho-McNeil Pharmaceutical Corporation. His expertise in creating effective pharmaceutical formulations has established him as a key figure in drug development processes aimed at improving patient outcomes.

Collaborations: Greco’s collaborative efforts have included working alongside talented professionals such as Michael Hawkins and Eugene Powell. These partnerships have been instrumental in enhancing the research and development of innovative pharmaceutical solutions.

Conclusion: Michael Nicholas Greco continues to be a leading innovator in the pharmaceutical industry, with a focus on developing targeted therapies for cancer treatment through his extensive patent portfolio. His dedication to advancing medical science through innovative formulations showcases his impact on the field and marks him as a significant contributor to the ongoing fight against cancer.

Profile summary based on public USPTO records.

Please report any incorrect information to [email protected]